Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Richard R. Furman et al.|Blood|2020Cited by 318
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Toby A. Eyre et al.|Blood|2021Cited by 70
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Townsend, William Wilson et al.|Blood Advances|2022Cited by 44
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b StudyNirav N. Shah, Talha Munir, Zulfa Omer et al.|Blood|2024Cited by 27
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCLGraham P. Collins, Dima El‐Sharkawi, William Townsend et al.|Blood|2023Cited by 9